Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP-204
- Development stage
- Preclinical
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
AIP-204 is a therapeutic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP Medical) for the treatment of lung cancer. Currently in the preclinical stage of development, AIP-204 is designed to selectively target lung cancer cells and deliver localized ionizing radiation to induce tumor cell death while minimizing exposure to healthy surrounding tissues. As part of AIP Medical's oncology pipeline, this agent represents a targeted approach to lung cancer therapy. Specific details regarding its molecular target, radioisotope, and chemical structure have not been publicly disclosed by the developer.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on AIP-204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP-204.